CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Troponin I Point of Care Testing for Patients with Suspected Acute Coronary Syndrome or Myocardial Infarction: Clinical Utility, Cost-Effectiveness and Guidelines

Last updated: March 31, 2020
Project Number: RB1463-000
Product Line: Rapid Response
Research Type: Device
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical utility of troponin I point of care testing for patients with chest pains, suspected acute coronary syndrome or myocardial infarction?
  2. What is the cost-effectiveness of troponin I point of care testing for patients with chest pains, suspected acute coronary syndrome or myocardial infarction?
  3. What are the evidence-based guidelines regarding the use of troponin I point of care testing in non-emergency department settings?

Key Message

​No relevant literature was identified regarding the clinical utility or cost-effectiveness of troponin I point of care testing for patients with chest pains, suspected acute coronary syndrome or myocardial infarction. In addition, no evidence-based guidelines were identified regarding the use of troponin I point of care testing in non-emergency department settings.